Use of Protease or a Protease Inhibitor for the Manufacture of Medicaments
AssigneeYeda Research and Development Co. Ltd.
InventorsTsvee Lapidot, Orit Kollet
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with the development and/or course of the disease.
Claims53
A method of treating a disease in a subject wherein the development and/or course of said disease involves SDF-1 activity and/or concentration, said method comprising administering to the subject a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of inducing mobilization of stem cells in a subject in need thereof, comprising administering to said subject a composition comprising a CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer in a pharmaceutically acceptable carrier.
A method of increasing retention of stem cells in the bone marrow in a subject in need thereof, comprising administering to said subject CTK1.
A method of treating a disease which its development and course is affected by SDF-1 activity and/or concentration, comprising administration of an effective amount of CTKI or a CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof.
A method of treating cancer in a mammal, comprising administering to the mammal an effective amount of CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof.
A method of modulating targeting of pluripotent stem cells to tissues comprising the administration of an effective amount of a CTKI or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in a subject in need.
A method of reducing the rate of hematopoietic cell multiplication, comprising administering an effective amount of a CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof to the hematopoietic cells.
A method of identifying a CTK antagonist comprising contacting CTK with SDF-1, measuring the activity of SDF-1 and isolating a compound capable of preventing or reversing inhibition of SDF-1 activity by CTK.
A method of identifying a CTK antagonist comprising contacting CTK with SDF-1, checking the integrity of SDF-1 and isolating a compound capable of preventing the degradation SDF-1 activity by CTK.
Dependencies are inferred from the claim text.